Umbutho wezeMpilo weHlabathi (i-WHO) ubhengeze namhlanje ukuba i-GlaxoSmithKline (GSK) iya kuhlaziya ukuzinikela kwayo ekunikezeni ichiza le-deworming albendazole de kube ukupheliswa kwe-lymphatic filariasis njengengxaki yezempilo yoluntu. Ukongezelela, ngo-2025, iipilisi ezizigidi ezingama-200 ngonyaka kunyango lwe-STH ziya kunikelwa, kwaye ngo-2025, iipilisi ezizigidi ezi-5 ngonyaka kunyango lwe-cystic echinococcosis.
Esi sibhengezo samva nje sakhela kwisibophelelo seminyaka engama-23 sale nkampani sokulwa neZifo ezithathu ezingahoywanga zeTropiki (NTDs) ezithwaxa kakhulu ezinye zezona ndawo zihluphekayo kwihlabathi.
Ezi zibophelelo ziyinxalenye nje yokuzibophelela okumangalisayo okwenziwe yi-GSK namhlanje kwiNgqungquthela yeSifo seMalariya kunye neTropiki engahoywanga e-Kigali, apho babhengeze i-£ 1 yebhiliyoni yotyalo-mali kwiminyaka eyi-10 ukukhawulezisa inkqubela kwizifo ezosulelayo. - amazwe ingeniso. Upapasho ndaba zekhampani).
Uphando luza kugxila kumachiza amatsha kunye nezitofu zokugonya ukuthintela kunye nokunyanga isifo seengcongconi, isifo sephepha, i-HIV (nge-ViiV Healthcare) kunye nezifo ezingahoywayo zetropiki, kunye nokujongana nokumelana ne-antimicrobial, eqhubeka nokuchaphazela abona bantu basengozini kwaye ibangela ukufa kwabantu abaninzi. . Umthwalo wezifo kumazwe amaninzi anengeniso ephantsi udlula ama-60%.